283 related articles for article (PubMed ID: 9710364)
1. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
[TBL] [Abstract][Full Text] [Related]
2. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue.
Dörr U; Räth U; Sautter-Bihl ML; Guzman G; Bach D; Adrian HJ; Bihl H
Eur J Nucl Med; 1993 May; 20(5):431-3. PubMed ID: 8100192
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
Filosso PL; Ruffini E; Oliaro A; Papalia E; Donati G; Rena O
Eur J Cardiothorac Surg; 2002 May; 21(5):913-7. PubMed ID: 12062286
[TBL] [Abstract][Full Text] [Related]
4. [Primary and follow-up studies of patients with carcinoid metastases using indium 111 octreotide--rational use of Sandostatin].
Lipp RW; Hammer HF; Passath A; Dobnig H; Ramschak-Schwarzer S; Stiegler C; Leb G; Krejs GJ
Acta Med Austriaca; 1993; 20(1-2):42-4. PubMed ID: 8475679
[TBL] [Abstract][Full Text] [Related]
5. [A case of rectal carcinoid with multiple liver, lymph nodes and bone metastases that responded to an octreotide therapy].
Yamashita K; Takase S; Nakamura T; Matsuda Y; Imanishi T; Sumi Y; Suzuki S; Kamigaki T; Ku Y; Kuroda D
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2349-51. PubMed ID: 21224569
[TBL] [Abstract][Full Text] [Related]
6. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
7. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
8. Octreoscan in patients with bronchial carcinoid tumours.
Granberg D; Sundin A; Janson ET; Oberg K; Skogseid B; Westlin JE
Clin Endocrinol (Oxf); 2003 Dec; 59(6):793-9. PubMed ID: 14974924
[TBL] [Abstract][Full Text] [Related]
9. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
[TBL] [Abstract][Full Text] [Related]
10. Octreotide scanning for carcinoid tumours.
Critchley M
Postgrad Med J; 1997 Jul; 73(861):399-402. PubMed ID: 9338023
[TBL] [Abstract][Full Text] [Related]
11. Use of somatostatin analog for localization and treatment of ACTH secreting bronchial carcinoid tumor.
Christin-Maitre S; Chabbert-Buffet N; Mure A; Boukhris R; Bouchard P
Chest; 1996 Mar; 109(3):845-6. PubMed ID: 8617102
[TBL] [Abstract][Full Text] [Related]
12. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
[No Abstract] [Full Text] [Related]
13. In-111 labeled octreotide imaging of a primary carcinoid lesion undetected by conventional imaging studies in a patient with "chronic pancreatitis".
Kummar S; Kim SL; Halkar RK; Galt JR
Clin Nucl Med; 1996 Aug; 21(8):634-7. PubMed ID: 8853917
[TBL] [Abstract][Full Text] [Related]
14. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature.
Leong WL; Pasieka JL
J Surg Oncol; 2002 Mar; 79(3):180-7. PubMed ID: 11870669
[TBL] [Abstract][Full Text] [Related]
15. Carcinoid of the pancreas.
Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
[TBL] [Abstract][Full Text] [Related]
16. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
[TBL] [Abstract][Full Text] [Related]
17. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.
Imtiaz KE; Monteith P; Khaleeli A
Clin Endocrinol (Oxf); 2000 Dec; 53(6):755-8. PubMed ID: 11155099
[TBL] [Abstract][Full Text] [Related]
18. The tumour vanishes.
Todd JF; Meeran K
Clin Endocrinol (Oxf); 2000 Dec; 53(6):663-4. PubMed ID: 11155085
[No Abstract] [Full Text] [Related]
19. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.
Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B
Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177
[TBL] [Abstract][Full Text] [Related]
20. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]